(Wall Street Journal) – Agency is missing deadlines and not responding to biotech companies, forcing some to push back clinical trials

Significant delays in the FDA’s core functions—such as approving amendments to clinical trials and guiding companies through processes for drug approval—are hindering the ability to develop drugs, say industry officials. Those setbacks are contributing to drugs taking longer to get through clinical trials and ultimately reach patients—and straining dollars for testing new possible treatments, say people familiar with the matter. (Read More)